Darryl Johnson, DO
Obstetrics & Gynecology · Ames, IANPI 1720084916
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $293 and has fallen 93.0% since, to $21 in 2024.
Across 64 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$191
- Johnson & Johnson$175
- Boehringer Ingelheim$127
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$105
- Sunovion Pharmaceuticals Inc.$58
- Novo Nordisk$58
- plus $231 from 12 others
What the payments were for
- Food & beverage$944100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 14 | $191 |
| Johnson & Johnson | 13 | $175 |
| Boehringer Ingelheim | 7 | $127 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $105 |
| Sunovion Pharmaceuticals Inc. | 5 | $58 |
| Novo Nordisk | 3 | $58 |
| AbbVie | 3 | $49 |
| Lilly USA, LLC | 2 | $25 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Urovant Sciences Inc | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Exeltis, USA Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Merck | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Eisai Inc. | 1 | $11 |
How this compares
$944 in reported general payments places this provider in the 65th percentile of 274 obstetrics & gynecology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 16 | $990 |
| Medroxyprogesterone Acetate | 61 | $691 |
| Mometasone Furoate | 42 | $677 |
| Oxybutynin Chloride ErOxybutynin Chloride | 51 | $662 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Ames
- Joyce LinesAmes$4K
- Emily ZoulekAmes$3K
- Mary RottoAmes$2K
- Jorge SotolongoCouncil Bluffs$171K
- Laura NealDubuque$157K
- Amy BingamanDes Moines$44K
- Alvadore OsbornWest Des Moines$34K
- Jason RexrothCedar Rapids$16K
- Maxwell MageeWest Des Moines$16K
- Lori PlattCouncil Bluffs$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.